EZH2 and cancer: For instance, enhancer of zeste homolog 2 (EZH2), which is a well-known histone-lysine N-methyltransferase enzyme, was found highly expressed in a variety of cancers, and a selective inhibitor such as tazemetostat that block EZH2 activity was shown to exert profound anti-tumor effects [16, 17].